{
    "id": 1548,
    "fullName": "CCND1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CCND1 over exp indicates an over expression of the CCND1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 595,
        "geneSymbol": "CCND1",
        "terms": [
            "CCND1",
            "BCL1",
            "D11S287E",
            "PRAD1",
            "U21B31"
        ]
    },
    "variant": "over exp",
    "createDate": "08/29/2014",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8444,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) resulted in a decreased response in ERBB2 (HER2) receptor positive breast cancer cells with induced overexpression of CCND1 in culture (PMID: 26977878).",
            "molecularProfile": {
                "id": 1571,
                "profileName": "CCND1 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8443,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Herceptin (trastuzumab) resulted in a decreased response in ERBB2 (HER2) receptor positive breast cancer cells with induced overexpression of CCND1 in culture (PMID: 26977878).",
            "molecularProfile": {
                "id": 1571,
                "profileName": "CCND1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6660,
                    "pubMedId": 26977878,
                    "title": "Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26977878"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 940,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, the CDK4/6 inhibitor LY2835129 reversed resistance to vemurafenib due to CCND1 upregulation in melanoma xenograft models (PMID: 25122067).",
            "molecularProfile": {
                "id": 1571,
                "profileName": "CCND1 over exp"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 616,
                    "pubMedId": 25122067,
                    "title": "The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122067"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Selumetinib (AZD6244) acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1517,
                "therapyName": "Palbociclib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1066,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and BEZ235 acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1515,
                "therapyName": "BEZ235 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1060,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Adrucil (fluorouracil) acted synergistically to decrease proliferation and survival of pancreatic cancer cell lines with a loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1509,
                "therapyName": "Fluorouracil + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and AZD0855 acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1520,
                "therapyName": "AZD8055 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic cancer cell lines with a loss of CDKN2A, upregulation of CCNE1 and CCND1 conferred resistance to Ibrance (palbociclib) treatment in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1068,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Apitolisib (GDC-0980) acted synergistically to decrease proliferation and survival of pancreatic cancer cells with loss of CDKN2A and upregulation of CCNE1 and CCND1 in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 1516,
                "therapyName": "GDC-0980 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1699,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Pimasertib acted synergistically to decrease proliferation of pancreatic cancer cell lines with loss of CDKN2A and upregulation of CCNE1 and CCND1in culture (PMID: 25156567).",
            "molecularProfile": {
                "id": 2398,
                "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss"
            },
            "therapy": {
                "id": 2016,
                "therapyName": "Palbociclib + Pimasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 780,
                    "pubMedId": 25156567,
                    "title": "CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25156567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7146,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2334470 moderately inhibited growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 3662,
                "therapyName": "GSK2334470",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7144,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PNU-74654 did not inhibit growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 2454,
                "therapyName": "PNU-74654",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7141,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 efficiently inhibited survival of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC156529 efficiently inhibited survival of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 4085,
                "therapyName": "NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7147,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3039478 and NSC156529 combination treatment resulted in improved growth inhibition over single drug treatment in primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 4383,
                "therapyName": "LY3039478 + NSC156529",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 did not inhibit growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7145,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 moderately inhibited growth of primary liver cancer cells over expressing target genes of the Notch (HES1, HEY1, TRIB2, NOTCH3, CCND1) and Hedgehog (GLI1, GLI2) pathways in culture (PMID: 27103434).",
            "molecularProfile": {
                "id": 24497,
                "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6106,
                    "pubMedId": 27103434,
                    "title": "The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103434"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ccnd1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26481,
                "profileName": "CCND1 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ccnd1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26482,
                "profileName": "CCND1 over exp PIK3CA E545K"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1571,
            "profileName": "CCND1 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4827,
                    "name": "CDK4/6 Inhibitor",
                    "profileName": "CCND1 over exp"
                }
            ]
        },
        {
            "id": 2398,
            "profileName": "CCND1 over exp CCNE1 over exp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24497,
            "profileName": "CCND1 over exp GLI1 over exp GLI2 over exp HES1 over exp HEY1 over exp NOTCH3 over exp TRIB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26481,
            "profileName": "CCND1 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26482,
            "profileName": "CCND1 over exp PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32363,
            "profileName": "CCND1 over exp FCER2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32364,
            "profileName": "CCND1 over exp FCER2 neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}